Showing results (31-40 of 307) with videos related to
Sort By:
Pageof 31
Revue Medicale Suisse|March 11, 2026
[Rheumatoid arthritis pathogenesis. From susceptibility to autoimmunity, and arthritis]Matthias Jarlborg, Cem Gabay, Axel FinckhPraxis|October 18, 2018
[Therapy of Psoriasis Arthritis Taking into Account New Treatment Options]Christina Ryser, Adrian CiureaAnnals of the Rheumatic Diseases|February 11, 2015
Impaired response to treatment with tumour necrosis factor α inhibitors in smokers with axial spondyloarthritisAdrian Ciurea, Almut Scherer, Ulrich Weber, et al.Revue Medicale De La Suisse Romande|November 24, 2004
[Review of the protective effects of tumor necrosis factor inhibitors in rheumatoid arthritis]Axel Finckh, Cem Gabay, Pierre-André GuerneNutrients|January 5, 2021
The Role of Nutritional Factors and Intestinal Microbiota in Rheumatoid Arthritis DevelopmentDeshiré Alpízar-Rodríguez, Axel Finckh, Benoît GilbertRheumatology (Oxford, England)|January 27, 2021
Predictive value of anti-CarP and anti-PAD3 antibodies alone or in combination with RF and ACPA for the severity of rheumatoid arthritisCeline Lamacchia, Delphine S Courvoisier, Matthias Jarlborg, et al.Rheumatology (Oxford, England)|April 30, 2015
Effectiveness of biologic DMARDs in monotherapy versus in combination with synthetic DMARDs in rheumatoid arthritis: data from the Swiss Clinical Quality Management RegistryCem Gabay, Myriam Riek, Almut Scherer, et al.Frontiers in Oral Health|May 23, 2022
Periodontitis in First Degree-Relatives of Individuals With Rheumatoid Arthritis: A Short Narrative ReviewAlkisti Zekeridou, Benoit Gilbert, Axel Finckh, et al.Therapeutics and Clinical Risk Management|May 14, 2008
A systematic review of infliximab in the treatment of early rheumatoid arthritisSophie Martin Du Pan, Cem Gabay, Axel FinckhClinical Therapeutics|June 15, 2019
Preferences of Patients and At-risk Individuals for Preventive Approaches to Rheumatoid ArthritisMarie Falahee, Axel Finckh, Karim Raza, et al.Pageof 31